We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

1 hedge funds and large institutions have $5.52K invested in Alexion Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Accent Capital Management
Ohio
+$5.52K

Top Sellers

No sellers this quarter

ALXN Hedge Fund Activity: Q2 2025 in Review

1 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2025, worth a combined $5.52K.

Buyers outnumbered sellers: 1 fund opened new ALXN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Accent Capital Management, opening a new position worth an estimated $5.52K.

  • 1 institutional investor held Alexion Pharmaceuticals (ALXN) as of Q2 2025, up from 0 in Q1 2025.
  • Funds reported $5.52K of Alexion Pharmaceuticals stock for Q2 2025.
  • 1 fund opened new Alexion Pharmaceuticals positions in Q2 2025 and 0 closed out, a net change of +1 holder.
  • The largest Alexion Pharmaceuticals buyer in Q2 2025 was Accent Capital Management, an estimated $5.52K added.

Based on aggregated 13F filings for Q2 2025.